CD71/TFRC/Transferrin Receptor Antibody (PA-1): sc-69737

CD71 Antibody (PA-1) is a mouse monoclonal IgG1 antibody that detects CD71 in human samples through immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD71, also known as transferrin receptor (TFR), is a type II membrane glycoprotein that plays a crucial role in iron homeostasis by facilitating cellular uptake of iron through receptor-mediated endocytosis. CD71 exists as a disulfide-linked homodimer, binding to two molecules of transferrin, which is essential for transporting iron to cells, particularly in proliferating cells, reticulocytes, and erythroid precursors. CD71 expression is typically high in these cell types, while resting leukocytes do not express CD71; however, CD71 expression increases upon activation of lymphocytes, monocytes, and macrophages, highlighting CD71′s importance in immune responses and cellular proliferation. CD71 is present on brain endothelium and is critical for maintaining iron levels in the central nervous system. A second transferrin receptor, TFR2, primarily expressed in the liver and mediating transferrin-bound iron uptake, underscores the complexity of iron regulation in the body. Mutations in the TFR2 gene can lead to hereditary hemochromatosis type III (HFE3), an iron overload disorder that predominantly affects Caucasians, further emphasizing CD71′s significance in both health and disease. Anti-CD71 antibody (PA-1) is an invaluable tool for researchers studying iron metabolism and related disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD71/TFRC/Transferrin Receptor Antibody (PA-1) References:

1. Prolongation of pancreatic islet graft survival by blocking transferrin receptor (CD71).  |  Rastellini, C., et al. 2001. Transplant Proc. 33: 518-9. PMID: 11266934
2. 1-40 Beta-amyloid protein fragment modulates the expression of CD44 and CD71 on the astrocytoma cell line in the presence of IL1beta and TNFalpha.  |  Speciale, L., et al. 2003. J Cell Physiol. 196: 190-5. PMID: 12767055
3. Expansion of mobilized peripheral blood progenitor cells under defined culture conditions rsing CD34+CD71-CD45- cells as a starting population.  |  Zech, NH., et al. 2003. J Hematother Stem Cell Res. 12: 367-73. PMID: 12965074
4. Immunohistochemical analysis of CD71, CD98 and CD99 activation antigens in human palatine and nasopharyngeal tonsils.  |  Sokmensuer, LK., et al. 2005. Saudi Med J. 26: 385-9. PMID: 15806204
5. Differential expressions of CD25 or CD71 on CD4+ and/or CD8+ tumor cells from a patient with adult T-cell leukemia/lymphoma: three color flowcytometric analysis of peripheral blood and lymph node.  |  Omata, F., et al. 1992. Am J Hematol. 40: 160-1. PMID: 1585922
6. Iron oxide-transfection agent complexes are not expected to coat the cell membrane and prevent CD71 expression.  |  Janic, B. and Arbab, AS. 2008. Radiology. 247: 914; author reply 914-5. PMID: 18487547
7. CD71 phenotype and the value of gallium imaging in lymphomas.  |  Feremans, W., et al. 1991. Am J Hematol. 36: 215-6. PMID: 1996560
8. NSOM/QD-based fluorescence-topographic image fusion directly reveals nano-spatial peak-valley polarities of CD69 and CD71 activation molecules on cell-membrane fluctuations during T-cell activation.  |  Zhong, L., et al. 2011. Immunol Lett. 140: 44-51. PMID: 21704079
9. In vitro T cell activation in elderly individuals: failure in CD69 and CD71 expression.  |  Lio, D., et al. 1996. Mech Ageing Dev. 89: 51-8. PMID: 8819106
10. Bone marrow steady-state CD34+/CD71- cell content is a predictive value of rG-CSF-mobilized CD34+ cells.  |  Osma, MM., et al. 1998. Bone Marrow Transplant. 21: 983-5. PMID: 9632270

The preferred CD71/TFRC/Transferrin Receptor antibody is CD71/TFRC/Transferrin Receptor Antibody (3B8 2A1): sc-32272.